Omalizumab effectiveness in SAA patients: the STELLAIR study @EuropeanRespiratory
Omalizumab effectiveness in SAA patients: the STELLAIR study  @EuropeanRespiratory
Uploaded May 2018 | Updated November 2026, 3 days ago
Lead author Professor Marc Humbert, MD, PhD, discusses key findings from the STELLAIR study paper 'Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count', published in the European Respiratory Journal.

Access the article: erj.ersjournals.com/content/51/5/1702523
Omalizumab effectiveness in SAA patients: the STELLAIR studyERS Vision: Better Drug delivery - improving device selection and patient complianceERS Congress 2018 Interview: Peter Gibson (session highlight)ERS Vision: Bridging the Health Divide in EuropeTurkish Thoracic Society Promo videoBe prepared: the importance of healthcare worker vaccination against influenzaERS Vision: Ageing and Respiratory MedicineERS Congress 2018 Interview: Philip Hansbro (session highlight)ERJ Open ResearchSleep and Breathing 2017: Be a part of Europes largest sleep and breathing conferenceOpening Ceremony: ELF Award: Yvo de Boer (5/7)ERS Vision - Unmet needs in pulmonary hypertension
European Respiratory Society |

Omalizumab effectiveness in SAA patients: the STELLAIR study

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER